Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Aducanumab and the FDA — where are we now?

(2021) Howard Fillit et al.   Nature Reviews Neurology

Monoclonal Antibodies as Neurological Therapeutics

(2021) Panagiotis Gklinos et al.   Pharmaceuticals

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Aducanumab for Alzheimer Disease

(2021) G. Caleb Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

(2021) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Critical Appraisal of Amyloid Lowering Agents in AD

(2021) Boris Decourt et al.   Current Neurology and Neuroscience Reports

Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent

(2021) Winston Chiong et al.   NEUROLOGY

Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab

(2021) Jacob N. Hall et al.   JAMA Neurology

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

(2021) Stephen Salloway et al.   JAMA Neurology

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

(2020) Samantha Budd Haeberlein et al.   Alzheimers & Dementia

Alzheimer disease and aducanumab: adjusting our approach

(2019) Dennis J. Selkoe   Nature Reviews Neurology

A resurrection of aducanumab for Alzheimer's disease

(2019) Lon Schneider   LANCET NEUROLOGY

Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways

(2019) Steven M. Greenberg et al.   Nature Reviews Neurology

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

(2017) Jia-Jie Mo et al.   Annals of Clinical and Translational Neurology

Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model

(2016) Ines Blockx et al.   JOURNAL OF ALZHEIMERS DISEASE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

(2015) Jeff Sevigny et al.   Alzheimers & Dementia

MR Imaging Features of Amyloid-Related Imaging Abnormalities

(2013) J. Barakos et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease

(2010) S Sakura Minami et al.   Journal of Neuroinflammation